<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Open Forum Infect Dis</journal-id><journal-id journal-id-type="iso-abbrev">Open Forum Infect Dis</journal-id><journal-id journal-id-type="publisher-id">ofid</journal-id><journal-title-group><journal-title>Open Forum Infectious Diseases</journal-title></journal-title-group><issn pub-type="epub">2328-8957</issn><publisher><publisher-name>Oxford University Press</publisher-name><publisher-loc>US</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">5632200</article-id><article-id pub-id-type="doi">10.1093/ofid/ofx163.757</article-id><article-id pub-id-type="publisher-id">ofx163.757</article-id><article-categories><subj-group subj-group-type="heading"><subject>Abstracts</subject><subj-group subj-group-type="category-toc-heading"><subject>Poster Abstract</subject></subj-group></subj-group></article-categories><title-group><article-title>Persistence of Bactericidal Activity at 4 Years After 2 Primary Doses of a Recombinant, 4-Component, Meningococcal Serogroup B Vaccine (4CMenB) and Response to a Booster Dose in Adolescents and Young Adults</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Nolan</surname><given-names>Terry</given-names></name><degrees>MBBS PhD</degrees><xref ref-type="aff" rid="AF0001">1</xref></contrib><contrib contrib-type="author"><name><surname>Garfield</surname><given-names>Hartley</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0002">2</xref></contrib><contrib contrib-type="author"><name><surname>Gupta</surname><given-names>Anil</given-names></name><degrees>MD CCFP</degrees><xref ref-type="aff" rid="AF0002">2</xref></contrib><contrib contrib-type="author"><name><surname>Ferguson</surname><given-names>Murdo</given-names></name><degrees>MBChB</degrees><xref ref-type="aff" rid="AF0003">3</xref></contrib><contrib contrib-type="author"><name><surname>Marshall</surname><given-names>Helen</given-names></name><degrees>MD MBBS</degrees><xref ref-type="aff" rid="AF0004">4</xref></contrib><contrib contrib-type="author"><name><surname>D&#x02019;Agostino</surname><given-names>Diego</given-names></name><degrees>MSc</degrees><xref ref-type="aff" rid="AF0005">5</xref></contrib><contrib contrib-type="author"><name><surname>Toneatto</surname><given-names>Daniela</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0006">6</xref></contrib></contrib-group><aff id="AF0001">
<label>1</label>
<institution>University of Melbourne and Murdoch Children&#x02019;s Research Institute</institution>, <addr-line>Melbourne, Victoria</addr-line>, <country>Australia</country></aff><aff id="AF0002">
<label>2</label>
<institution>University of Toronto</institution>, <addr-line>Toronto, ON</addr-line>, <country>Canada</country></aff><aff id="AF0003">
<label>3</label>
<institution>Colchester Research Group</institution>, <addr-line>Truro, NS</addr-line>, <country>Canada</country></aff><aff id="AF0004">
<label>4</label>
<institution>University of Adelaide and Women&#x02019;s and Children&#x02019;s Hospital</institution>, <addr-line>Adelaide, South Australia</addr-line>, <country>Australia</country></aff><aff id="AF0005">
<label>5</label>
<institution>GSK, Amsterdam</institution>, <country>Netherlands</country></aff><aff id="AF0006">
<label>6</label>
<institution>GSK</institution>, <addr-line>Siena</addr-line>, <country>Italy</country></aff><author-notes><fn id="fn-0001"><p>
<bold>Session:</bold> 140. Assorted Pediatric Vaccines</p><p>
<italic>Friday, October 6, 2017: 12:30 PM</italic>
</p></fn></author-notes><pub-date pub-type="collection"><season>Fall</season><year>2017</year></pub-date><pub-date pub-type="epub" iso-8601-date="2017-10-04"><day>04</day><month>10</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>04</day><month>10</month><year>2017</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>4</volume><issue>Suppl 1</issue><issue-title>ID Week 2017 Abstracts</issue-title><fpage>S322</fpage><lpage>S322</lpage><permissions><copyright-statement>&#x000a9; The Author 2017. Published by Oxford University Press on behalf of Infectious Diseases Society of America.</copyright-statement><copyright-year>2017</copyright-year><license license-type="cc-by-nc-nd" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com</license-p></license></permissions><self-uri xlink:href="ofx163.757.pdf"/><abstract><title>Abstract</title><sec id="s1"><title>Background</title><p>This phase 3b, open label, controlled, multi-center, extension study (NCT02446743) assessed the persistence of bactericidal activity at 4&#x000a0;years post-primary vaccination with a recombinant, 4-component, meningococcal serogroup B vaccine (4CMenB) in adolescents who participated in the parent study NCT01423084 and their response to a booster dose, compared with that in vaccine-na&#x000ef;ve healthy controls.</p></sec><sec id="s2"><title>Methods</title><p>Adolescents and young adults previously primed with 4CMenB (2 doses; following a 0,1-month schedule) in study NCT01423084 (group 3B) and vaccine-na&#x000ef;ve 15&#x02013;22&#x000a0;year olds (group B0_1) were enrolled. Group&#x000a0;3B received a booster dose of 4CMenB at 4&#x000a0;years post-primary vaccination; group B0_1 received 2 catch-up doses of 4CMenB (following a 0,1-month schedule). Antibody persistence (primary objective) was evaluated at 4&#x000a0;years post-primary vaccination (in group 3B) <italic>vs.</italic> baseline (in group B0_1) using human serum bactericidal assay (hSBA), in terms of geometric mean titer (GMT) and percentage (%) of individuals with hSBA titer at least 4.&#x000a0;Immune responses at 1&#x000a0;month after booster dose (in group 3B) <italic>vs.</italic> those at 1&#x000a0;month after first dose (in group B0_1) were also assessed.</p></sec><sec id="s3"><title>Results</title><p>In group 3B, antibody levels declined from 1&#x000a0;month to 4&#x000a0;years post-primary vaccination against all antigens except NHBA, but were higher than in group B0_1 at baseline (Table), with a GMT ratio &#x02265;1.3 and a difference in % of individuals with hSBA titer at least 4 of &#x02265;9%. After one dose of 4CMenB (booster in 3B or first dose in B0_1), GMTs increased (&#x02265;4.6-fold in group 3B; &#x02265;2.3-fold in group B0_1), and &#x02265;94% of participants in group 3B and &#x02265;41% of participants in group B0_1 had hSBA titer at least 4 (Table).</p><fig fig-type="figure" id="F1" orientation="portrait" position="float"><graphic xlink:href="OFIDIS_ofx163_IF0311"/></fig></sec><sec id="s4"><title>Conclusion</title><p>Antibody levels in adolescents and young adults primed with 4CMenB waned over time but were higher at 4&#x000a0;years post-primary vaccination than for vaccine-na&#x000ef;ve individuals at baseline. A&#x000a0;booster dose of 4CMenB in vaccine-primed individuals elicited higher immune responses than one dose of 4CMenB in vaccine-na&#x000ef;ve individuals.</p><p>The research was supported by GlaxoSmithKline Biologicals&#x000a0;SA.</p></sec><sec id="s5"><title>Disclosures</title><p>
<bold>T. Nolan</bold>, GSK group of companies: Research Contractor and Scientific Advisor, Research grant. Pfizer: Research Contractor, Research grant. <bold>H. Garfield</bold>, Novartis/GSK group of companies: Investigator, Research support. <bold>A. Gupta</bold>, Novartis/GSK group of companies: Investigator, payment for research-related activities; <bold>M. Ferguson</bold>, GSK group of companies: Investigator, I&#x000a0;receive salary from CRG. CRG has contracts with GSK. <bold>H. Marshall</bold>, GSK group of companies: Grant Investigator and Investigator, Research grant. Pfizer: Grant Investigator and Investigator, Research&#x000a0;grant; sanofi pasteur: Grant Investigator, Research grant. Novavax: Investigator, Research grant. <bold>D. D&#x02019;Agostino</bold>, GSK group of companies: Consultant, Consulting fee. <bold>D. Toneatto</bold>, GSK group of companies: Employee, Salary.</p></sec></abstract><counts><page-count count="1"/></counts></article-meta></front></article>